BehavioSec Granted U.S. Patents for Mobile Authentication and Social Engineering Detection
16.6.2021 10:00:00 EEST | Business Wire | Press release
BehavioSec, the industry pioneer and technology leader for behavioral biometrics and continuous authentication, today announced the successful grant of two additional U.S. patents for its innovative method of verifying user identity and detecting fraud. Since its 2008 founding, BehavioSec has successfully been granted 24 U.S. patents, demonstrating the company’s continual commitment to the innovation and development of behavioral biometrics technology. With this new addition to their patent portfolio, BehavioSec technology can better protect digital identities and consumers on mobile devices from increasingly sophisticated, social engineering attacks – helping stop fraud before the damage is done.
Today, BehavioSec already protects over 180 million people and 20 billion annual transactions across the globe. But as mobile devices continue to increase as a means of conducting financial transactions and accessing account information, consumers and institutions are often trading security and placing more value on the convenience and experience of using them. The new BehavioSec patent US20200074053A1 offers a leap forward in protecting the over 3 billion Android devices in use today. The technology behind this patent allows BehavioSec customers to double the actionable intelligence gleaned from each Android keystroke – without friction, latency, or intrusive data collection. This new technology also instantly matches mobile digital identities against their inherent and unique behavioral biometrics profiles – securing them from fraud like banking trojans, remote access attacks, device theft, and social engineering scams.
For social engineering scams (when legitimate customers are tricked or coached into fraudulent transactions), the new BehavioSec patent US20210117979A1 improves the detection and blocking of these scams at scale. It is a further advancement of the company’s 2019 patent US20200118138A1 that enhanced accuracy and added new methods of detection on mobile devices. With this defensive layer, institutions have greater sensitivity and visibility into subtle behavioral anomalies resulting from stress, hesitation, and duress, which are often key indicators that an attack like voice phishing or authorized push payment (APP) fraud is occurring. These types of fraud methods are typically invisible to traditional methods like device fingerprinting or knowledge-based challenges and can only be detected at scale by employing continuous authentication using frictionless technologies like behavioral biometrics.
“In order to reduce fraudulent activity, customers need to be protected where it matters most, their digital identity,” said Neil Costigan, CEO at BehavioSec. “These additions to our patent portfolio are geared towards increasing visibility and improving detection capabilities to offer our customers the most comprehensive security, fighting fraud before it happens.”
Today’s news comes on the heels of BehavioSec announcing SOC 2 compliance certification and new platform features (version 5.4) that boost enrollment speed, performance, and mobile fraud detection capabilities. For more information on the BehavioSec behavioral biometrics platform and how it safeguards users, visit www.behaviosec.com.
About BehavioSec
BehavioSec is the industry pioneer and technology leader for behavioral biometrics and continuous authentication, safeguarding millions of users and billions of transactions today.
Deployed across Global 2000 companies to dramatically reduce fraud, friction, threat, and theft, BehavioSec verifies and protects human digital identities by understanding how we uniquely type and swipe across our ever-changing devices. Whether used in the Cloud or on-premises, BehavioSec delivers the superior user experience, precision, and scale needed by organizations to keep customers engaged while catching evasive, real-time attacks other solutions miss.
Founded in the Nordics in 2008 out of groundbreaking research, industry-recognized BehavioSec partners with market leaders and organizations like DARPA, and has earned investment from top investment firms like Forgepoint Capital, Cisco, ABN AMRO, Conor Ventures, and Octopus Ventures. Headquartered in San Francisco, CA with offices worldwide, BehavioSec is ready to help you reduce risk, improve compliance, and digitally transform your distributed workforce and customer experience. www.behaviosec.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210616005121/en/
Contact information
Carrie VanBuskirk
W2 Communications
pr@behaviosec.com
571-247-1133
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Imagine Dragons to Perform at Abu Dhabi Grand Prix21.5.2026 18:51:00 EEST | Press release
Ethara, organiser of the Formula 1 Etihad Airways Abu Dhabi Grand Prix, have announced that one of the world’s biggest bands, Imagine Dragons, will headline the Saturday After-Race Concerts at the F1 Season Finale in Abu Dhabi. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521214839/en/ Imagine Dragons to perform at Formula 1 Etihad Airways Abu Dhabi Grand Prix (Photo: AETOSWire) The announcement is another landmark moment for the Abu Dhabi Grand Prix, whose thrilling Yasalam presented by e& fan entertainment offering has become synonymous with the F1 Championship finale in Abu Dhabi and is recognised as one of the most compelling sports and entertainment crossovers globally. The global chart-toppers join Lewis Capaldi and Zara Larsson, who are set to kick off a blockbuster line-up of performances on Yas Island on Thursday, 3 December, with more major international artists to be revealed. With their popular top hits, Ima
Otovo Hits 30,000 Customers in Under a Year, Tackling the Growing ‘Solar Service Crisis’21.5.2026 17:25:00 EEST | Press release
Otovo ASA (“Otovo”), a leading global energy service provider for residential and commercial customers, today announced it has reached 30,000 customers across the U.S. and Europe. A total of 20,000 customers have enrolled in Otovo Care, the Company’s membership-based home and commercial energy service, which is powered by Otovo’s industry-leading AI platform, Endurance™. “Reaching 30,000 customers in less than year is proof positive that home and business owners value their power systems,” said William J. (John) Berger, CEO of Otovo. “The ‘solar service crisis’ that is leaving millions of orphaned energy systems without support is driving strong interest in our Otovo Care membership program. Every day your home or commercial power system is not working, you are throwing money away. Otovo’s rapid response service platform keeps you up and running, ensuring your investment is delivering.” The rapid growth of the residential solar market created a growing population of “orphaned” solar sy
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 15:05:00 EEST | Press release
A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is designed to interpret cardiac MRI scans by connecting moving images of the heart with corresponding clinical radio
The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 15:00:00 EEST | Press release
Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The research challenges long-held assumptions about media value, showing that not all impressions are equal. Live sports rem
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 15:00:00 EEST | Press release
Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer cell killing activity,” said David Weinreich, MD, MBA, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “The Phase 3 study and the enrollment of the first patient with Precem-TcT build on the Company’s more than 20 years of expertise in colorectal cancer, and highlight our commitment to advancing differentiated ADCs for heavily pretreated patients with limited treatment options.” The PROCEADE®-CRC-03 study
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
